Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Yu Liu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Mr. Bekri Melka Abdo, Ethiopian Institute of Agricultural Research, Ethiopia

Bekri Melka Abdo is a dedicated organic chemist specializing in natural product chemistry 🌿. With expertise in plant sample collection, extraction, compound isolation, and structure elucidation, he focuses on bioactive compounds from Ethiopia’s medicinal and aromatic plants. His research contributes to developing natural product-based treatments for leishmaniasis 🦠. He has two published journal articles, an h-index of 7, a Google patent, and an ISBN-registered book 📖. Actively engaged in research and consultancy, Bekri is committed to innovative drug discovery and advancing natural product chemistry for global health.

Publication Profile

orcid

Education

Bekri Melka Abdo is a dedicated professional in organic chemistry 🧪, specializing in natural product chemistry 🌿. His expertise encompasses plant sample collection and preparation, extraction, compound isolation, and structure elucidation. He is skilled in qualitative and quantitative analysis, as well as biological activity determination of natural products extracted from various aromatic and medicinally significant 🌱 exotic and endemic plant species of Ethiopia. With a strong foundation in the field, he contributes to the discovery and characterization of bioactive compounds, supporting advancements in medicine, pharmaceuticals, and biotechnology 🔬. His research plays a vital role in exploring Ethiopia’s rich botanical resources.

Experience 

Bekri Melka Abdo is a passionate researcher in natural product chemistry 🌿, with a strong track record of research and innovation 🔬. He has successfully completed two research projects and maintains an h-index of 7 📊. His contributions extend to industry consultancy and collaborative projects, showcasing his impact in the field. He has authored a book with an ISBN 📖 and has a Google patent pending. His work is recognized in SCI and Scopus-indexed journals 🏅, with two publications. Actively engaged in editorial roles and professional memberships, he continues to drive scientific advancements in bioactive compound discovery.

Award

Bekri Melka Abdo, with his early career achievements and promising research in natural product chemistry 🌿, is an ideal candidate for the Young Scientist Award 🏆. His dedication to bioactive compound discovery, coupled with his impactful contributions to scientific research and innovation 🔬, highlights his potential for future breakthroughs. With a strong foundation in natural product extraction, analysis, and biological activity determination, he is paving the way for new discoveries in medicine and biotechnology 💊. This award category recognizes emerging researchers like Mr. Abdo, whose work demonstrates both excellence and the promise of transformative scientific advancements.

Research Focus

Mr. Bekri Melka Abdo specializes in phytochemistry and antiparasitic drug discovery, focusing on the bioassay-guided isolation of natural compounds for therapeutic applications. His research on dehydrocostus lactone from Echinops kebericho highlights its potential as a leishmanicidal drug 🦟⚕️. His work integrates natural product chemistry, pharmacognosy, and infectious disease research, contributing to novel drug development against leishmaniasis. By combining traditional medicinal plants with modern bioassays, he advances the search for effective, plant-derived antiparasitic treatments 🌱🔬. His research holds promise for addressing neglected tropical diseases through sustainable and nature-inspired therapies.

Publication Top Notes

Bioassay-guided isolation of dehydrocostus lactone from Echinops kebericho as a leishmanicidal drug

Edwin Posadas | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. 📚🔬✨

Publication Profile

orcid

Education

Dr. Edwin Posadas 🎓 began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) 🏥. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. 🔬💙

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) 🏥, Association of Philippine Physicians of America (1998) 🇵🇭, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) 🎖️. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) 🔬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) 🚀 and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine 🏥, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 🧬🎗️. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. 🔬💙

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer 🔬, metastasis 🧬, and nanotechnology-based diagnostics 🏥. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. 🎗️

Publication Top Notes

Determinants of Liver Metastasis

A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

A blood test to identify prostate cancer patients at risk for visceral metastasis

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling

FYN Is a Key Regulator of Metastasis in Prostate Cancer

Targeting FYN in Prostate Cancer: A Key Regulator of Growth and Motility

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2 Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Prof. Johan Alexander Villada Ramos, Universidad del Quindío, Colombia

Johan Alexander Villada Ramos is a Ph.D. candidate in Sciences at Universidad del Quindío, specializing in natural alternatives to synthetic pesticides 🌱🦠. He holds a Master’s in Biomedical Sciences, earning a meritorious distinction 🏅, and a Biology degree. His research spans bioactive plant compounds, cancer prevention, and lipid metabolism. As a university lecturer 📚, he teaches molecular biology and biochemistry. With multiple research projects, publications, and awards, including the Carlos Corredor Pereira National Award in Biomedical Sciences (2024) 🏆, Johan is a dedicated scientist pushing the boundaries of biotechnology and microbiology.

Publication Profile

Orcid

Education

Prof. Johan Alexander Villada Ramos 🎓 is a doctoral student in Sciences at the Universidad del Quindío, focusing on the bioactivity of free and microencapsulated Tagetes erecta L. 🌿 as an alternative to synthetic pesticides against the avocado weevil Heilipus lauri 🥑. He earned a Master’s in Biomedical Sciences (2018–2022) with meritorious distinction 🏅, researching the effects of Passiflora edulis extract on lipid metabolism enzymes in human colorectal adenocarcinoma cells. His Biology degree (2013–2018) involved evaluating the antibacterial activity of Tagetes patula L. against Ralstonia solanacearum. Additionally, he trained in microbiology and biotechnology lab preparation at SENA (2017–2018) 🔬.

Professional Achievements

Prof. Johan Alexander Villada Ramos 🎓 has made significant contributions to biomedical and biological research. He earned a meritorious distinction 🏅 for his master’s research on Passiflora edulis 🍊 and its effects on lipid metabolism in colorectal cancer cells. Holding a Biology degree 🔬, his studies focused on the antimicrobial activity of plant extracts against pathogens. He has been actively involved in high-impact research projects 📚 at prestigious institutions, including Pontificia Universidad Javeriana and Universidad del Quindío. His work continues to advance natural alternatives 🌱 in disease management, reinforcing his dedication to scientific discovery and innovation.

Leadership in Academia

Prof. Johan Alexander Villada Ramos 🎓 is a dedicated academic leader, serving as a lecturer 📖 in molecular biology, biochemistry, and microbiology 🔬 at Universidad del Quindío. Passionate about education, he actively contributes to curriculum development 🏫, ensuring that students receive up-to-date and high-quality training. Additionally, he plays a key role in laboratory training 🧪, equipping future scientists with essential research skills. His commitment to fostering scientific knowledge and practical expertise strengthens the university’s academic foundation, inspiring students to excel in the fields of biotechnology, microbiology, and biomedical sciences. 🚀

Research Focus

Prof. Johan Alexander Villada Ramos specializes in natural product chemistry, biochemistry, and phytopharmacology, with a strong focus on the antioxidant, antibacterial, and anticancer properties of plant extracts. His research explores bioactive compounds from medicinal plants, such as Coffea arabica ☕, Passiflora edulis 🍃, and Tagetes patula 🌼, investigating their effects on oxidative stress, protein oxidation, and bacterial inhibition 🦠. His studies contribute to pharmaceutical development, food science, and biomedicine, aiming to harness plant-derived compounds for disease prevention and therapeutic applications. 🏥

Publication Top Notes

Potencial antioxidante del extracto de hoja de Coffea arabica sobre la lipoperoxidación y oxidación proteica en un modelo de músculo bovino

Identification of potential bioactive compounds of Passiflora edulis leaf extract against colon adenocarcinoma cells

Evaluation of antibacterial activity of extract and essential oil of Tagetes patula L. in vitro against Ralstonia solanacearum biovar 2

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology 🧪. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) 📚. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. 🎓🔬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine 🏥. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant 📖. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies 🔬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) 🏥. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine 🔬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology 📚.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate 📚, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers 🔬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors 🏅. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology 🧠💊, medicinal chemistry ⚗️, and molecular neuroscience 🔬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems 🚀, enantiomeric drug behavior 🔄, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.

Publication Top Notes

Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers

Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif

Synthesis and Properties of a Water-Soluble Ureide Derived from Gаlodif and Succinic Acid

A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers

Effect of original anticonvulsant ortho-fluoro-benzonal on immune cells functional properties at chronic ethanol intoxication

The original anticonvulsant meta-Cl-benzhydrylurea (m-CL-BHM) induces of the liver monooxygenase system and stimulates the neuroimmune response in behavioral disorders of alcoholic origin

EMBRIOGENESIS OF NEURONAL ELENENTS (GLIOBLASTS AND GABAA RECEPTORS) IN THE HUMAN BRAIN NEUROIMMUNE SYSTEM UNDER PRENATAL ALCOHOL EXPOSURE

An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Ala Hssain | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ala Hssain | Drug Discovery and Development | Best Researcher Award

Ms Ala Hssain,University of Halabja,Iraq

Dr. Ala Hamd Hssain 🇮🇶 is a dedicated physicist specializing in material science and quantum mechanics. She earned her PhD in Material Science (2023) from Firat University, Turkey, and her Master’s in Quantum Mechanics (2014) from Eastern Mediterranean University, Cyprus. Currently, she is a faculty member at University of Halabja, Iraq, teaching quantum mechanics and advanced calculus. Her research focuses on DFT simulations, molecular modeling, and hydroxyapatite materials, with numerous publications in high-impact journals 📚. Proficient in Gaussian, Vesta, and Multiwfn, she actively contributes to scientific advancements in computational and experimental physics. ✨

Publication Profile

Scopus

Education

Ms. Ala Hssain 🎓 earned her Ph.D. in Material Science (2019-2023) from Firat University, Faculty of Science, Physics Department, in Elazig, Turkey 🇹🇷. She previously completed her Master’s degree in Quantum Mechanics (2012-2014) at Eastern Mediterranean University, Cyprus 🇨🇾, under the supervision of Prof. Dr. Habib Mazharimousavi. Her academic journey began with a Bachelor’s degree in Physics from Salahaddin University 🎓. With a strong foundation in physics and material science, she has dedicated her research to advancing knowledge in these fields, contributing to cutting-edge developments in quantum mechanics and material engineering. ⚛️🔬

Academic Experience

Ms. Ala Hssain 🎓 has a rich background in teaching and laboratory assistance. She served as an assistant physicist at the University of Sulaimani 🔬, working in optics, electricity, and measurement labs (2009-2010), solid-state and atomic labs (2010-2011), and atomic labs (2011-2012). Later, she became a lecturer at the University of Halabja 📚, teaching Calculus, scientific debate, atomic labs, metrology, and electricity & magnetism between 2014 and 2018. Currently, she continues her academic journey as a Quantum Mechanics professor ⚛️ for third-year students at the University of Halabja, contributing to the next generation of physicists. 🚀

Research Experience

Ms. Ala Hssain 🎓 is proficient in advanced computational tools for molecular simulations and density functional theory (DFT) 🔬. She has expertise in Gaussian software for molecular modeling, enabling precise quantum mechanical calculations ⚛️. Additionally, she is skilled in VESTA for 3D visualization of crystal structures 🏗️, VMD for molecular dynamics simulations 🧬, Multiwfn for wavefunction analysis 🌊, and Siesta for efficient DFT calculations on complex materials 🏢. Her expertise in these tools enhances her research in material science, quantum mechanics, and computational physics, contributing to innovative advancements in the field. 🚀

Academic Activities

Ms. Ala Hssain 🎓 has an extensive research portfolio, focusing on material science, quantum mechanics, and computational chemistry 🔬. Her publications explore hydroxyapatite co-doping, spinel synthesis, and optoelectronic compounds. Notable works include DFT modeling of Secnidazole 🧪, structural and spectroscopic studies on serotonin ⚛️, and Mg-doped Zn-based hydroxyapatites 🏗️. She has also contributed to theoretical and experimental research on L-tryptophan dimers 🧬. Published in prestigious journals like Chemical Physics Letters and Journal of Molecular Structure, her studies drive advancements in materials chemistry, nanotechnology, and molecular simulations. 🚀📖

Research Focus

Ms. Ala Hssain’s research focuses on Computational and Experimental Chemistry 🧪, particularly in the structural and spectroscopic analysis of biomolecules. Her work on the L-tryptophan dimer state involves a combination of Density Functional Theory (DFT)🖥️ and Molecular Dynamics (MD) simulations to understand molecular interactions and stability. This interdisciplinary research bridges theoretical modeling and experimental validation, contributing to fields like biophysics 🧬, pharmaceutical sciences 💊, and material chemistry 🔬. Her expertise lies in using computational tools to predict molecular behavior, aiding in drug design and biomolecular engineering. Her findings enhance the understanding of amino acid interactions in biological systems.

Publication Top Notes

Structural and spectroscopic study of L-tryptophan dimer state using DFT and MD: Computational and experimental analysis

Dr. ANANDARUP GOSWAMI| Drug Discovery and Developmenty|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANANDARUP GOSWAMI| Drug Discovery and Development|Best Researcher Award

Dr. ANANDARUP GOSWAMI at Vignan’s Foundation for Science, Technology and Research,India

PROFILE  

Google scholar

Early Academic Pursuits 🎓

Dr. Anandarup Goswami’s passion for chemistry was ignited during his early years of education. He completed his undergraduate studies with a B.Sc. (Hons.) in Chemistry from the prestigious Presidency University in Kolkata, one of India’s top institutions for the sciences. He further honed his expertise by pursuing an M.Sc. in Chemistry at the renowned Indian Institute of Technology (IIT) Kanpur, known for producing some of the finest scientific minds in the country. Dr. Goswami’s dedication to his academic pursuits earned him a place in Cornell University, USA, where he completed his Ph.D. His doctoral work marked the beginning of his contribution to cutting-edge research, where he specialized in advanced areas of chemistry. His journey did not stop there; he went on to complete his postdoctoral research at Rutgers University, USA, and Palacky University, Czech Republic, enhancing his research portfolio and gaining exposure to diverse scientific methodologies and innovative research techniques.

Professional Endeavors 🧪

Dr. Anandarup Goswami joined Vignan’s Foundation for Science, Technology and Research (VFSTR) as an Associate Professor in November 2026. His professional career spans a broad spectrum of roles, from teaching and mentoring students to leading groundbreaking research. He has served as a Ph.D. supervisor and has guided numerous students in drug degradation studies and nanocatalysis development for environmental applications. His work at VFSTR has helped shape the future of young scientists while driving forward critical research in sustainable chemistry.

Dr. Goswami also holds numerous editorial appointments, including being a member of the Editorial Board of Current Indian Science (Bentham) and a Review Editor for Green and Sustainable Chemistry (Frontiers). His contributions to these roles highlight his prominence in the scientific community, where he is trusted to review and oversee publications in these significant areas of research.

Contributions and Research Focus 🔬

Dr. Goswami’s research contributions are primarily centered around two critical areas: pharmaceutically relevant compounds and sustainable nanocatalysts. His extensive work in the isolation and in-depth characterization of degradation products of pharmaceutical compounds has significant implications for drug safety, efficacy, and regulatory science. In tandem, his pioneering work on the development of nanocatalysts for environmental applications addresses pressing issues related to sustainability and environmental protection.

Dr. Goswami’s work emphasizes catalysis, energy conversion, and material science, offering solutions to some of today’s most critical challenges. His contributions span more than 50 peer-reviewed publications, including in highly reputed journals such as Journal of the American Chemical Society (JACS), Angewandte Chemie, and Nature Chemistry. Moreover, his book, Solvent-Free Methods in Nanocatalysis: From Catalyst Design to Applications, co-edited with prominent scientists, reflects his authority in the field of nanocatalysis.

Accolades and Recognition 🏆

Dr. Goswami’s research accomplishments have been widely recognized in the scientific community. With an h-index of 27 on Google Scholar and 26 on Scopus, along with more than 8,800 citations, his work has made a lasting impact on his field. He has received recognition for his contributions to nanocatalysis and drug degradation, and his research has gained international acclaim.

One of his notable patents, US010722743B2, titled Multicatalyst Polyelectrolyte Membranes and Methods of Utilizing the Same, was developed during his time at Rutgers University, USA. This patent reflects his innovative approach to solving complex problems in material science and catalysis.

Dr. Goswami’s contributions have also led him to collaborate with renowned scientists globally, including Prof. Tewodros Asefa from Rutgers University, USA, and Prof. Radek Zboril from RCPTM, Czech Republic. These collaborations have expanded his research’s scope and influence, enabling him to contribute to international advancements in chemistry.

🎓Publication 

Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, François-Xavier Felpin, Tewodros Asefa, Xiaoxi Huang, Rafael Silva, Xiaoxin Zou, Radek Zboril, Rajender S Varma
  • Journal    :Chemical reviews
  • Year         :2016

obalt‐Embedded Nitrogen‐Rich Carbon Nanotubes Efficiently Catalyze Hydrogen Evolution Reaction at All pH Values

  • Authors   : Xiaoxin Zou, Xiaoxi Huang, Anandarup Goswami, Rafael Silva, Bhaskar R Sathe, Eliška Mikmeková, Tewodros Asefa
  • Journal    :Angewandte Chemie International Edition
  • Year         :2014

Core–shell nanoparticles: synthesis and applications in catalysis and electrocatalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, Tewodros Asefa, Huizhang Guo, Ankush V Biradar, Dong-Liang Peng, Radek Zboril, Rajender S Varma
  • Journal    :Chemical Society Reviews
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   : Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature chemistry
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   :Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature Publishing Group
  • Year         :2015